Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;23(11):2967-2979.
doi: 10.1111/codi.15848. Epub 2021 Aug 12.

A semi-Markov model comparing the lifetime cost-effectiveness of mesh prophylaxis to prevent parastomal hernia in patients undergoing end colostomy creation for rectal cancer

Collaborators, Affiliations

A semi-Markov model comparing the lifetime cost-effectiveness of mesh prophylaxis to prevent parastomal hernia in patients undergoing end colostomy creation for rectal cancer

Syed Mohiuddin et al. Colorectal Dis. 2021 Nov.

Abstract

Aim: Parastomal hernia (PSH) is a common problem following colostomy. Using prophylactic mesh during end colostomy creation may reduce PSH incidence, but concerns exist regarding the optimal type of mesh, potential long-term complications, and cost-effectiveness of its use. We evaluated the cost-effectiveness of mesh prophylaxis to prevent PSH in patients undergoing end colostomy creation for rectal cancer.

Methods: We developed a decision-analytical model, stratified by rectal cancer stages I-IV, to estimate the lifetime costs, quality-adjusted life-years (QALYs) and net monetary benefits (NMBs) of synthetic, biologic and no mesh from a UK NHS perspective. We pooled the mesh-related relative risks of PSH from 13 randomised controlled trials (RCTs) and superimposed these on the baseline (no mesh) risk from a population-based cohort. Uncertainty was assessed in sensitivity analyses.

Results: Synthetic mesh was less costly and more effective than biologic and no mesh to prevent PSH for all rectal cancer stages. At the willingness-to-pay threshold of £20,000/QALY, the incremental NMBs (95% CI) ranged between £1,706 (£1,692 to £1,720) (stage I) and £684 (£678 to £690) (stage IV) for synthetic versus no mesh, and £2,038 (£1,997 to £2,079) (stage I) and £1,671 (£1,653 to £1,689) (stage IV) for synthetic versus biologic mesh. Synthetic mesh was more cost-effective than no mesh unless the relative risk of PSH was ≥0.95 for stages I-III and ≥0.93 for stage IV. [Correction added on 05 October 2021 after first online publication: The estimation of health outcomes (QALYs) for all three interventions evaluated (synthetic mesh; biologic mesh; no mesh) have been corrected in this version.] CONCLUSIONS: Synthetic mesh was the most cost-effective strategy to prevent the formation of PSH in patients after end colostomy for any rectal cancer stage; however, conclusions are dependent on which subset of RCTs are considered to provide the most robust evidence.

Keywords: Markov model; biologic mesh; cost-effectiveness; parastomal hernia; stoma; synthetic mesh.

PubMed Disclaimer

References

REFERENCES

    1. National Bowel Cancer Audit (NBOCA) An audit of the care received by people with bowel cancer in England and Wales. 2020; Available from: https://www.nboca.org.uk/content/uploads/2020/12/NBOCA-2020-Annual-Repor.... Accessed 14 Feb 2020.
    1. Brandsma H-T, Hansson BME, Aufenacker TJ, van Geldere D, Lammeren FMV, Mahabier C, et al. Prophylactic mesh placement during formation of an end-colostomy reduces the rate of parastomal hernia: short-term results of the Dutch PREVENT-trial. Ann Surg. 2017;265(4):663-9.
    1. Carne PW, Robertson GM, Frizelle FA. Parastomal hernia. Br J Surg. 2003;90(7):784-93.
    1. Jänes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg. 2004;91(3):280-2.
    1. Odensten C, Strigård K, Rutegård J, Dahlberg M, Ståhle U, Gunnarsson U, et al. Use of prophylactic mesh when creating a colostomy does not prevent parastomal hernia: a randomized controlled trial-STOMAMESH. Ann Surg. 2019;269(3):427-31.

LinkOut - more resources